SAN RAMON, Calif., Aug. 11, 2017 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parenteral delivery needs, today provided a corporate update and reported financial results for the second quarter ended June 30, 2017.
Second Quarter 2017 and Recent Corporate Highlights Include:
